Hemostemix Inc. (CVE:HEM – Get Free Report)’s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of C$0.08 and traded as low as C$0.07. Hemostemix shares last traded at C$0.07, with a volume of 8,000 shares changing hands.
Hemostemix Price Performance
The stock has a market capitalization of C$6.10 million, a PE ratio of -3.50 and a beta of 0.20. The company has a 50 day moving average price of C$0.08 and a 200-day moving average price of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Read More
- Five stocks we like better than Hemostemix
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Top 3 Investment Themes to Watch for in 2025
- Stock Analyst Ratings and Canadian Analyst Ratings
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- The Significance of Brokerage Rankings in Stock Selection
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
